ConferencePoster
 (2022)

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Monk, Bradley; Tewari, Krishnansu; Dubot, Coraline; Caceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Gümü?, Mahmut; Olivera, Mivael et al